Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS1 | P23219 | 1/20 | 0.66 |
| ▸ | GNRHR | P30968 | 3/20 | 0.60 |
| ▸ | ABCC2 | Q92887 | 1/20 | 0.59 |
| ▸ | C5AR1 | P21730 | 2/20 | 0.54 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.51 |
| ▸ | NMBR | P28336 | 2/20 | 0.50 |
| ▸ | GRPR | P30550 | 2/20 | 0.50 |
| ▸ | CTSL | P07711 | 2/20 | 0.48 |
| ▸ | CTSS | P25774 | 2/20 | 0.48 |
| ▸ | CTSK | P43235 | 2/20 | 0.48 |
| ▸ | CTSH | P09668 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29833852 | 0.97 | PTGS1 (0.69) | PTGS1GNRHRABCC2C5AR1OPRM1 | |
| SCHEMBL29833864 | 0.97 | PTGS1 (0.69) | PTGS1GNRHRABCC2C5AR1OPRM1 | |
| SCHEMBL29584427 | 0.96 | PTGS1 (0.71) | PTGS1GNRHRABCC2C5AR1NMBR | |
| SCHEMBL29833877 | 0.94 | PTGS1 (0.65) | PTGS1GNRHRABCC2C5AR1OPRM1 | |
| SCHEMBL29833897 | 0.94 | PTGS1 (0.65) | PTGS1GNRHRABCC2C5AR1OPRM1 | |
| SCHEMBL29833884 | 0.94 | PTGS1 (0.75) | PTGS1GNRHRABCC2NMBRGRPR | |
| SCHEMBL29833876 | 0.94 | PTGS1 (0.75) | PTGS1GNRHRABCC2NMBRGRPR | |
| SCHEMBL29833848 | 0.94 | PTGS1 (0.75) | PTGS1GNRHRABCC2NMBRGRPR | |
| SCHEMBL29833875 | 0.94 | PTGS1 (0.75) | PTGS1GNRHRABCC2NMBRGRPR | |
| SCHEMBL29833863 | 0.94 | PTGS1 (0.75) | PTGS1GNRHRABCC2NMBRGRPR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240033320-A1 | IMMUNORHELIN COMPOUNDS FOR INTRACELLULAR INFECTIONS | ISR Immune System Regulation Holding AB (publ) (SE) | 2024-02-01 | — | — | US | disclosed |
| US-11672842-B2 | Gonadotropin-releasing hormones for use as adjuvant immunotherapeutics | ISR Immune System Regulation Holding AB (publ) (SE) | 2023-06-13 | — | — | US | disclosed |
| US-20230118205-A1 | NOVEL COMPOUNDS (IMMUNORHELINS) | ISR IMMUNE SYSTEM REGULATION HOLDING AB PUBL (SE) | 2023-04-20 | — | — | US | disclosed |
| US-11564969-B2 | Immunorhelin compounds for intracellular infections | ISR Immune System Regulation Holding AB (publ) (SE) | 2023-01-31 | — | — | US | disclosed |
| US-11434258-B2 | Compounds (immunorhelins) | ISR Immune System Regulation Holding AB (SE) | 2022-09-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230118205-A1 | NOVEL COMPOUNDS (IMMUNORHELINS) | GNRHR, FSHR, LHCGR | PTGS1 3702/4885GNRHR 1/4885ABCC2 4865/4885 |
| US-20240033320-A1 | IMMUNORHELIN COMPOUNDS FOR INTRACELLULAR INFECTIONS | GNRHR, GHRHR, FSHR | PTGS1 3887/4885GNRHR 1/4885ABCC2 4820/4885 |
| US-11564969-B2 | Immunorhelin compounds for intracellular infections | GNRHR, GHRHR, FSHR | PTGS1 3887/4885GNRHR 1/4885ABCC2 4820/4885 |
| US-11434258-B2 | Compounds (immunorhelins) | GNRHR, FSHR, LHCGR | PTGS1 3304/4885GNRHR 1/4885ABCC2 4867/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.